NCT02403271View on ClinicalTrials.gov

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

124

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions

Non-Small Cell Lung CancerBreast CancerPancreatic Cancer

Interventions

DRUG

Ibrutinib

BTK Inhibitor

DRUG

Durvalumab

Anti PDL-1

Trial Locations (17)

27710

Durham

32610

Gainesville

32806

Orlando

35294

Birmingham

37212

Nashville

38120

Germantown

60637

Chicago

61615

Peoria

77030

Houston

78229

San Antonio

85258

Scottsdale

90025

Los Angeles

90048

Los Angeles

92093

La Jolla

94115

San Francisco

94305

Palo Alto

07601

Hackensack

Sponsors

Lead Sponsor

Pharmacyclics LLC.

All Listed Sponsors

lead

Pharmacyclics LLC.

INDUSTRY